NFKB1 and rheumatoid arthritis: Numerous inhibitors have been designed to efficiently block distinct steps of NF‐κB signalling, including inhibitors of IKK activity, proteasome, nuclear translocation and DNA binding activity; however, there are still no clinically available selective NF‐κB‐based drugs for RA treatment [40, 41].